HALDOL by Johnson & Johnson is unclear. Approved for schizophrenia in adults. First approved in 1971.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
HALDOL (haloperidol) is a small-molecule antipsychotic approved in 1971 for treating schizophrenia in adults via injectable formulation. It works primarily as a dopamine D2 receptor antagonist in the central nervous system, with secondary activity at alpha-1 adrenergic receptors. The mechanism effectively reduces psychotic symptoms through dopaminergic modulation.
As LOE approaches with moderate competitive pressure (30), brand teams face contraction; focus shifts to niche positioning and retention of long-standing patient populations rather than market expansion.
unclear. However, its effect in schizophrenia could be mediated through its activity as an antagonist at central dopamine type 2 receptors. Haloperidol also binds to alpha-1 adrenergic receptors, but with lower affinity, and displays minimal binding to muscarinic cholinergic and histaminergic (H 1…
Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
Worked on HALDOL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on HALDOL offers limited career growth due to its LOE-approaching lifecycle and absence of active job openings (0 linked positions). This role is best suited for professionals seeking stability in a legacy brand or transition experience rather than high-impact commercial expansion.